Supplemental Figure 3a from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 3a. PTEN IHC assay validation and scoring. PTEN IHC was performed on a panel of FFPE breast cancer cell pellets of known PTEN status confirmed by western immunoblot. (A.) Western immunoblot analyses for MDA-MB-468, CAL-148, MDA-MB-361, MT-3, and MDA-MB-436 human breast cancer cell lines are illustrated above with PTEN IHC illustrated below.